Patterns of Care in Maintenance Therapy in US Patients Undergoing Definitive Chemoradiation for Stage 3 Non-Small Cell Lung Cancer (NSCLC).
Adolescent
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal
/ therapeutic use
Antineoplastic Agents, Immunological
/ therapeutic use
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Chemoradiotherapy
Drug Utilization
/ statistics & numerical data
Female
Humans
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Young Adult
Journal
American journal of clinical oncology
ISSN: 1537-453X
Titre abrégé: Am J Clin Oncol
Pays: United States
ID NLM: 8207754
Informations de publication
Date de publication:
01 02 2022
01 02 2022
Historique:
pubmed:
7
1
2022
medline:
15
2
2022
entrez:
6
1
2022
Statut:
ppublish
Résumé
The recommended treatment for patients with unresectable stage 3 non-small cell lung cancer (NSCLC) is definitive chemoradiation followed by 1 year of maintenance durvalumab. Our objective was to assess the rate of maintenance durvalumab use after chemoradiation. Analyses were conducted in both open claims (IQVIA pharmacy and medical claims data) and adjudicated closed claims (IQVIA PharMetrics Plus Health Plan Claims Database). Patients with a lung cancer diagnosis between November 2017 and November 2020 who received definitive chemoradiation were included. Of the 5802 NSCLC patients included in the open claims source, 1794 (31%) received durvalumab, 1403 (24%) received maintenance chemotherapy, and 2605 (45%) did not receive any maintenance therapy. Of the 239 NSCLC patients included in the closed claims source, 127 (53%) received durvalumab, 40 (17%) received maintenance chemotherapy, and 72 (30%) did not receive any maintenance therapy. The most common maintenance chemotherapy agents patients received were carboplatin, pemetrexed, and paclitaxel. The rate of durvalumab utilization was overall low in both the open and closed claims data sources (31% and 53%, respectively). It remains unknown what percent of eligible patients end up receiving durvalumab, as our analysis was unable to filter out patients who were unfit for durvalumab or if they had progression after chemoradiation. Future efforts are needed to increase maintenance durvalumab utilization and to determine how best to manage patients who are unfit for durvalumab.
Identifiants
pubmed: 34991107
doi: 10.1097/COC.0000000000000886
pii: 00000421-202202000-00001
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antineoplastic Agents, Immunological
0
durvalumab
28X28X9OKV
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
49-54Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
National Comprehensive Cancer Network (NCCN). Non–small cell lung. NCCN Guidelines; 2021.
Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med. 2017;377:1919–1929.
Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379:2342–2350.
Yusuf D, Walton RN, Hurry M, et al. Population-based treatment patterns and outcomes for stage III non-small cell lung cancer patients: a real-world evidence study. Am J Clin Oncol. 2020;43:615–620.
Gerber DE, Schiller JH. Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea. J Clin Oncol. 2013;31:1009–1020.
Brule S. Second line and maintenance therapy for advanced non-small cell lung cancer without driver mutation: an evolving paradigm. Int J Cancer Clin Res. 2016;3:1–7.
Maguire FB, Morris CR, Parikh-Patel A, et al. First-line systemic treatments for stage IV non-small cell lung cancer in California: patterns of care and outcomes in a real-world setting. JNCI Cancer Spectr. 2019;3:1–9.
Kehl KL, Hassett MJ, Schrag D. Patterns of care for older patients with stage IV non-small cell lung cancer in the immunotherapy era. Cancer Med. 2020;9:2019–2029.
Tran Q, Warren JL, Barrett MJ, et al. An evaluation of the utility of big data to supplement cancer treatment information: linkage between IQVIA Pharmacy Database and the Surveillance, Epidemiology, and End Results Program. J Natl Cancer Inst Monogr. 2020;2020:72–81.
Stewart M, Norden AD, Dreyer N, et al. An exploratory analysis of real-world end points for assessing outcomes among immunotherapy-treated patients with advanced non–small-cell lung cancer. JCO Clin Cancer Inform. 2019;3:1–15.
Kurosky S, Klein AB, Parikh RC. Clinical characteristics, treatment patterns, and health care resource utilization in unresectable, locally advanced, stage III non-small cell lung cancer: a medical record review study in the United States and Canada. Value Health. 2018;21:S49–S50.
Lee JS, Kim S, Sung S-Y, et al. Treatment outcomes of 9994 patients with extensive-disease small-cell lung cancer from a retrospective nationwide population-based cohort in the Korean HIRA Database. Front Oncol. 2021;11:1–8.
Connor S, Orfanos P, Flahavan E, et al. Methodological approaches for incorporating real-world data (RWD) for overall survival (OS) into long-term survival estimates: a case-study NICE technology appraisal in extensive-stage small cell lung cancer (ES-SCLC). Value Health. 2019;53:S921.
Cotarla I, Boron ML, Cullen SL, et al. Treatment decision drivers in stage III non–small-cell lung cancer: outcomes of a web-based survey of oncologists in the United States. JCO Oncol Pract. 2020;16:e1232–e1242.
West HJ. Jarring discordance between idealized and real-world management in stage III non–small-cell lung cancer. JCO Oncol Pract. 2020;16:628–630.
Eichkorn T, Bozorgmehr F, Regnery S, et al. Consolidation immunotherapy after platinum-based chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer—cross-sectional study of eligibility and administration rates. Front Oncol. 2020;10:1–9.
Ronden MI, Bahce I, Claessens NJM, et al. The impact of the availability of immunotherapy on patterns of care in stage III NSCLC: a dutch multicenter analysis. JTO Clin Res Rep. 2021;2:100195.